HPV Testing And Pap Test Market Report 2026

HPV Testing And Pap Test Market Overview

• HPV Testing And Pap Test market size has reached to $4.83 billion in 2025 • Expected to grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: The Increase In The Prevalence Of High-Risk HPV Infections Fueling The Growth Of The HPV Testing And Pap Test Market Due To Ageing Unvaccinated Cohorts • Market Trend: Innovative Rapid, Low-Cost Screening Kits Boost Early Detection Of Cervical Cancer In India • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HPV Testing And Pap Test Market?

HPV testing and Pap tests refer to screening tests used to detect cervical cancer in women. These tests are used to detect early signs of abnormal changes that could lead to cancer. The main types of HPV testing and Pap tests are HPV testing and Pap tests. HPV testing refers to a medical procedure in which a healthcare provider checks for the presence of the human papillomavirus (HPV) in a patient's body. The main products are instruments, consumables, and services that use technologies such as polymerase chain reaction (PCR), immunodiagnostics, and other technologies. It is used in cervical cancer screening and vaginal cancer screening by hospitals and clinics, laboratories, and other end users.

What Is The HPV Testing And Pap Test Market Growth Forecast?

The hpv testing and pap test market size is expected to see rapid growth in the next few years. It will grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of molecular diagnostic technologies, rising demand for early cancer detection, expansion of population-based screening initiatives, growing use of automated laboratory systems, increasing healthcare investments in preventive diagnostics. Major trends in the forecast period include increasing adoption of hpv dna-based screening tests, rising use of liquid-based cytology methods, growing integration of automated diagnostic platforms, expansion of co-testing approaches for cervical screening, enhanced focus on early cancer detection accuracy.

Global HPV Testing And Pap Test Market Segmentation

1) By Test Type: HPV Testing, Pap Test 2) By Product: Instruments, Consumables, Services 3) By End User: Hospitals And Clinics, Laboratories, Other End Users Subsegments: 1) By HPV Testing: High-Risk HPV Testing, HPV Genotyping 2) By Pap Test: Conventional Pap Test, Liquid-Based Pap Test, Pap Plus HPV Testing

What Is The Driver Of The HPV Testing And Pap Test Market?

An increase in the prevalence of cervical cancer is driving the HPV testing and Pap test markets. Cervical cancer refers to the disease that causes uncontrollable growth in the cells of the cervix. The rise in cervical cancer prevalence is primarily due to the lack of regular screening, which prevents early detection and timely treatment of precancerous changes. Increasing cervical cancer can be controlled using early detection, which can be achieved using HPV testing and Pap tests. For instance, in May 2025, according to the Cancer Council Australia, an Australia-based national nonprofit organization, in 2023, 231 females in Victoria were diagnosed with invasive cervical cancer, which corresponds to a current diagnosis rate of 6.4 cases per 100,000 females. Therefore, the increase in the prevalence is driving the growth of the HPV testing and Pap test industry.

Key Players In The Global HPV Testing And Pap Test Market

Major companies operating in the hpv testing and pap test market are Abbott Laboratories, QIAGEN N V, Becton Dickinson and Company, Hologic Inc, F Hoffmann La Roche AG, Seegene Inc, DiaSorin S p A, Genomica S A U, TruScreen Group Limited, Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Takara Bio Inc, Fujirebio Diagnostics Inc, Randox Laboratories Ltd, Quidel Corporation, Vela Diagnostics, Greiner Bio One International GmbH, Cepheid, Roche Diagnostics International AG, Genedrive plc

Global HPV Testing And Pap Test Market Trends and Insights

Major companies in the HPV and Pap test market are focusing on developing innovative solutions such as rapid, low-cost, and point-of-care screening kits to improve early detection and accessibility of cervical cancer testing. Rapid, low-cost, point-of-care screening kits are medical tests that deliver quick results, are affordable, and can be used directly at clinics or community settings without needing complex laboratory infrastructure. For instance, in April 2025, the Department of Biotechnology, an India-based government agency, launched HPV test kits for cervical cancer screening. These kits offer rapid, point-of-care detection of high-risk HPV genotypes responsible for over 96% of cervical cancer cases, enabling faster and more accurate screening. They are affordable and designed for use in resource-limited settings, facilitating widespread accessibility in rural and urban healthcare facilities. These kits aid India’s cervical cancer prevention efforts by providing a cost-effective alternative to traditional screening methods, supporting the WHO goal of 70% screening coverage by 2030.

What Are Latest Mergers And Acquisitions In The HPV Testing And Pap Test Market?

In February 2025, Metropolis Healthcare, an India-based diagnostics company, partnered with Roche Diagnostics to launch HPV DNA testing in India, aimed at strengthening early cervical cancer screening by combining Metropolis’ nationwide lab network with Roche’s advanced molecular diagnostics technology. Roche Diagnostics is a Switzerland-based healthcare and diagnostics company, known for its expertise in in-vitro diagnostics, molecular testing, and oncology-focused screening solutions.

Regional Outlook

North America was the largest region in the HPV testing and Pap test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global HPV testing and Pap tests market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the HPV Testing And Pap Test Market?

The HPV testing and Pap test market consists of revenues earned by entities by conventional Pap tests, liquid-based Pap test, HPV DNA test, and co-testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The HPV testing and Pap test market also consists of sales of HPV testing and Pap test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.